Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type

Eur Neuropsychopharmacol. 1992 Jun;2(2):149-55. doi: 10.1016/0924-977x(92)90025-4.


Thirty-three patients with mild primary degenerative dementia according to DSM-III (MMS between 15 and 27) took part in a double-blind cross-over study of phosphatidylserine (Fidia, 300 mg/d) versus placebo. Both treatment phases lasted for 8 weeks with an 8 week washout phase in between and a 4 week washout phase before treatment phase one. Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one. The improvement carried over to the following wash-out and treatment phases. There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency. 16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group. BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Brain Mapping
  • Double-Blind Method
  • Electroencephalography
  • Evoked Potentials, Somatosensory
  • Humans
  • Middle Aged
  • Phosphatidylserines / therapeutic use*
  • Psychiatric Status Rating Scales
  • Psychometrics


  • Phosphatidylserines